| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We reviewed corrected serum Ca levels at initial onset (n=683) and/or as of recurrence (n=71) in patients with RCC. We also examined a total of 623 renal tumor samples for PTHLH mRNA expressions by quantitative real-time PCR. High serum Ca concomitant with PTHLH overexpression in tumors was observed exclusively in clear cell RCC but not in other non-clear cell tumors. In clear cell RCC, univariate and multivariate Cox analyses demonstrated that high PTHLH expression was strongly associated with poor overall survival for patients who underwent standard nephrectomy. Moreover, in stage IV advanced cases, PTHLH expressions remained as independent prognostic parameters for OS in multivariate Cox model. These data suggest that the previously characterized tumor signatures of high serum Ca due to high PTHLH expression and poor prognosis are clear cell RCC-specific features, and detection of tumor PTHLH expression will be a potent diagnostic and prognostic marker for clear cell RCCs.
|
